Aarkstore 2012 The Latest Reports || Endpoints - Clinical Trials in CNS Disorders - Multiple

FOR IMMEDIATE RELEASE
(Free-Press-Release.com) February 16, 2012 -- RSS Aarkstore.com announces, a new market research report is available in its vast collection:

Endpoints - Clinical Trials in CNS Disorders - Multiple Endpoints and Ratings Scales are Becoming More Widely Adopted

http://www.aarkstore.com/reports/Endpoints-Clinical-Trials-in-CNS-Disorders-Multiple-Endpoints-and-Ratings-Scales-are-Becoming-More-Widely-Adopted-170853.html




Summary

Company, the leading business intelligence provider, has released its latest research “Endpoints - Clinical Trials in CNS Disorders - Multiple Endpoints and Ratings Scales are Becoming More Widely Adopted” which provides an insight into different endpoints that are used for the central nervous system (CNS) in clinical trials. The report examines different aspects under clinical trial endpoints in central nervous system disorders such as analysis on major marketed central nervous system drugs with an emphasis on safety and efficacy details. Phase II and Phase III clinical trial analysis for both completed and ongoing clinical trials, most promising central nervous system drugs with details on safety, efficacy and clinical trials, and terminated trial analysis. The company profiling highlights the central nervous system drugs of different companies.

Scope :

- Data and analysis on the marketed products and analysis of their efficacy and safety details
- Analysis of the five major Central nervous system diseases which include Alzheimer’s disease, depression, epilepsy, Parkinson’s disease and schizophrenia
- Analysis of the Phase III and Phase II clinical trials in terms of percentage cases. Also analysis of terminated trials is included in this chapter. Only industry sponsored studies are included in the report.



Table of Contents :

1 Table of Contents 3

1.1 List of Tables 5
1.2 List of Figures 7
2 Clinical Trial Design in Central Nervous System - Overview 12
2.1 Introduction 12
2.2 Types of Clinical Trial Outcomes 12
2.2.1 Primary Outcomes 12
2.2.2 Secondary Outcomes 12
2.3 GBI Research Report Guidance 13
3 Endpoints - Clinical Trials in CNS Disorders - Top Five CNS Disorders and their Product Profiling 14
3.1 Endpoints-Major Marketed Drugs of Top Five Central Nervous System Disorders and their Regulatory Approval 14
3.1.1 Alzheimer’s disease 15
3.1.2 Depression 15
3.1.3 Epilepsy 16

3.1.4 Parkinson’s disease 16
3.1.5 Schizophrenia 17
4 Endpoints - Clinical Trials in CNS Disorders –Marketed and Pipeline Product Assessments 18
4.1 Alzheimer’s disease 18
4.1.1 Primary Endpoints used in Alzheimer’s disease Clinical Trials 19
4.1.2 Secondary Endpoints used in Alzheimer’s disease Clinical Trials 19
4.1.3 Major Marketed Drugs-Safety and Efficacy Analysis 19
4.1.4 Phase III Clinical Trial Analysis 25
4.1.5 Most Promising Drugs’ Profiles 41
4.1.6 Phase II Clinical Trial Analysis 45
4.1.7 Terminated Trials Analysis 61
4.2 Depression 62

4.2.1 Primary Endpoints used in Clinical Trials for Depression 63

For more related Reports Plz follow The link:
http://www.aarkstore.com/search/viewresults.asp?search=Endpoints&PubId=&pagenum=1

More Reports:
http://www.aarkstore.com/reports/Renal-Dialysis-Services-Global-Opportunity-Assessment-Competitive-Landscape-and-Market-Forecasts-to-2017-170022.html

http://www.aarkstore.com/reports/Transcatheter-Heart-Valve-Market-to-2017-Improvements-in-Design-and-Technique-and-a-Favorable-Reimbursement-Scenario-to-Contribute-to-Higher-Procedure-Volumes-178255.html

http://www.aarkstore.com/reports/Orphan-Autoimmune-Disorders-to-2017-Strong-Performance-by-Nplate-and-Promacta-and-Future-Launches-of-Immunoglobulin-Therapies-will-Drive-the-ITP-Market-170858.html





For More details Plz do contact :

Aarkstore Enterprise

Phone:08149852585

Email: enquiry@aarkstore.com

EndpointClinicalTrialsDisorder